Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 780 matching trials from the live ClinicalTrials.gov search.
Conditions
Advance Solid Tumors
Interventions
KIVU-107
Drug
Lead sponsor
Kivu Bioscience Inc.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Santa Monica, California • New Have, Connecticut
Conditions
Bladder Cancer
Interventions
Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
566
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 342 more
Conditions
Mucopolysaccharidosis Type II (MPS II)
Interventions
RGX-121
Genetic
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
5 Years to 17 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Oakland, California
Conditions
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4S Neuroblastoma
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 18 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Non Small Cell Lung Carcinoma NSCLC
Interventions
Durvalumab (MEDI4736), Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Anaheim, California
Conditions
Advanced Solid Tumors
Interventions
ADCT-601, Gemcitabine
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Santa Monica, California • Stanford, California • Iowa City, Iowa + 3 more
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
clofarabine, melphalan, gene expression analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation
Drug · Genetic · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
1 Year to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Duarte, California
Conditions
HIV Infections
Interventions
Placebo, Aprepitant
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Not applicable Interventional

Student Anxiety & Stress Study

NCT03986125
Conditions
Anxiety, Somatic Symptom Disorder
Interventions
Emotional Awareness & Expression Therapy, Mindfulness Meditation Training
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Tumor, Tumors Metastatic to Brain, Adult Anaplastic Oligoastrocytoma
Interventions
bafetinib, microdialysis, pharmacological study, liquid chromatography, mass spectrometry, laboratory biomarker analysis, protein expression analysis, western blotting, immunohistochemistry staining method, therapeutic conventional surgery
Drug · Procedure · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Duarte, California • South Pasadena, California
Conditions
Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Protocol for Women at Increased Risk of Developing Breast Cancer

NCT00291694
Conditions
Breast Cancer
Interventions
celecoxib, placebo
Drug · Other
Lead sponsor
Carol Fabian, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Triple Negative Breast Cancer
Interventions
adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment
Biological · Device · Other
Lead sponsor
OBI Pharma, Inc
Industry
Eligibility
18 Years and older
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
12
States / cities
La Jolla, California • San Diego, California • San Francisco, California + 9 more
Conditions
Liver Cancer
Interventions
bevacizumab, dexamethasone, floxuridine, protein expression analysis, flow cytometry, immunoenzyme technique, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging
Biological · Drug · Genetic + 2 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
2
States / cities
New York, New York
Completed Phase 2 Interventional Results available

Phase II Study of Digitoxin to Treat Cystic Fibrosis

NCT00782288
Conditions
Cystic Fibrosis
Interventions
digitoxin, placebo
Drug · Other
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab soravtansine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 8 more
Recruiting No phase listed Observational Accepts healthy volunteers

Pancreatic Cancer Detection Consortium

NCT06388967
Conditions
Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer Stage I, Pancreatic Cancer Stage, Pancreatic Cancer Resectable, Pancreatic Cancer Stage 0, Pancreatic Cancer Stage II, Pancreatic Cancer Stage III, Pancreatic Cancer, Adult, Pancreatic Cancer Non-resectable
Interventions
PANcreatic cancer Exosome Early detectiON (PANXEON)
Diagnostic Test
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
11
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Monrovia, California + 8 more
Conditions
Esophagus Cancer, Esophageal Cancer Stage, Esophageal Cancer, Esophageal Neoplasms, Esophagus Adenocarcinoma, Esophagus, Barrett, Barrett Esophagus, Barrett Adenocarcinoma, Barrett Epithelium, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia, Barretts Esophagus With High Grade Dysplasia, Barretts Esophagus With Low Grade Dysplasia, Barrett Esophagus, Long-Segment, Barrett's Esophagus With Dysplasia, Unspecified, Barrett's Esophagus With Esophagitis, Gastroesophageal Reflux, Reflux Disease, Esophageal Adenocarcinoma, Esophageal Dysplasia, Esophageal Neoplasms Malignant
Interventions
EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia)
Diagnostic Test
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
658 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Duarte, California
Conditions
Cutaneous Melanoma
Interventions
Not listed
Lead sponsor
Castle Biosciences Incorporated
Industry
Eligibility
16 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia • Louisville, Kentucky • St Louis, Missouri
Conditions
Stress Disorders, Post-Traumatic
Interventions
Prolonged Exposure (PE), Treatment as usual group therapy (TUGT), Supportive counseling (SC)
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 67 Years · Female only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Conditions
Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer), Cancer, Colon Cancer, Rectal Cancer, Lung Cancer, CRC, Head and Neck Squamous Cell Cancer, HNSCC, Renal Cell Carcinoma, RCC, Kidney Cancer, Triple Negative Breast Cancer, TNBC, Colorectal Adenocarcinoma
Interventions
A2B395, xT CDx with HLA-LOH assay
Biological · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
10
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 7 more
Conditions
Leukemia
Interventions
imatinib mesylate, gene expression analysis, mutation analysis, polymerase chain reaction, flow cytometry, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
4
States / cities
Buffalo, New York • Durham, North Carolina • Cleveland, Ohio
Recruiting Not applicable Interventional Accepts healthy volunteers

Human Intracranial Electrophysiology

NCT05529264
Conditions
Epilepsy
Interventions
Memory Tasks, Attention/arousal tasks, Language tasks, Visuospatial tasks, Auditory Tasks, Brain Stimulation, Social Emotional Task, Recording of facial expressions, Judgement/Impulsivity Task
Other · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2032
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Pneumonia, Pulmonary Disease, Lung Disease
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
3 Years to 99 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Bethesda, Maryland